肿瘤治疗新技术 医术天地

  • 用微信扫描以下二维码

    更多移动资讯等着你

  • 抗癌故事

肿瘤治疗新技术

首页
/
最新疗法
/
抗癌故事
/
癌症论坛
/
抗癌头条
/
名医博客
/
肿瘤问答
/
医学文献
/
健康大数据
/

VEGF的表达是胰腺癌术后化疗是否有效的重要指标 019

楼主:暖南绿倾i2017-03-21 05:24 只看楼主

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
导读:VEGF的表达是胰腺癌术后化疗是否有效的重要指标
         关键词: VEGF的表达是胰腺癌术后化疗是否有效的重要指标  来源: 九州抗癌药物网
在ASCO的2005年的胃肠肿瘤座谈会上,Khorana作了“VEGF的表达是胰腺癌术后化疗是否有效的指标”的报告。血管生成是胰腺癌进展的重要过程,VEGF是促进血管生成的重要因子,DPC4是血管生成的抑制因子,Khorana等对128例手术切除的胰腺癌组织进行微阵列分析,发现有术后胰腺癌需要辅助化疗的预后指标有:
1.VEGF表达
2.DPC4缺失
3.高的微血管密度的
有以上任一指标的患者接受术后化疗比不接受有更长的生存期,并且有统计学意义。
  该研究有一定的局限性:
1.回顾性研究
2.没有对年龄和性别进行匹配
3.辅助化疗没有标准化
4.对于那些局限表达的病人,低估了其真正的表达率
screen.width-333)this.width=screen.width-333" border=0>
screen.width-333)this.width=screen.width-333" border=0>
screen.width-333)this.width=screen.width-333" border=0>
screen.width-333)this.width=screen.width-333" border=0>
VEGF expreion predicts adjuvant therapy outcomes in resected pancreatic cancer 
Author(s): A. A. Khorana, C. K. Ryan, Y. C. Hu, R. A. Komorowski, S. A. Ahrendt
Atract: Background: Angiogenesis is important for the progreion of pancreatic cancer, but its predictive &#118alue is not known. We investigated the aociation of various angiogenic factors and microveel deity (MVD) with adjuvant therapy and prognosis in resected pancreatic cancer. Methods: Tiue cores from a multi-ititutional retroective series of 128 resected patients were used to build a pancreatic cancer tiue microarray. Vascular endothelial growth factor (VEGF), platelet-derived endothelial cell growth factor (PD-ECGF), CD31 (for MVD) and DPC4 expreion were determined using immunohistochemistry. Results: Expreion of VEGF and PD-ECGF, both proangiogenic factors, was oerved in 74 (58%) and 75 (59%) tumors, reectively. Expreion of DPC4, an angiogenesis inhibitor, was oerved in 59(46%) tumors. VEGF expreion correlated significantly with increased MVD (p=0.03). Pancreatic cancers with lo of the angiogenesis inhibitor DPC4 also showed increased MVD (p=0.05). However, PD-ECGF expreion did not correlate with MVD. Median survival in patients with VEGF-negative tumors was longer than in those with VEGF-positive tumors (20.2 versus 14.7 month HR 0.71, 95%CI, 0.51-1.12; p=0.16). Use of adjuvant therapy was aociated with increased survival in patients with VEGF-positive tumors (18.9 [treated] versus 11.2 [untreated] month HR 0.38, 95%CI, 0.19-0.76; p=0.005). However, no survival benefit from adjuvant therapy was oerved in patients with VEGF-negative tumors. Conversely, adjuvant therapy was aociated with significantly increased survival in patients with lo of angiogenesis inhibitor DPC4 (20.3 [treated] versus 11.2 [untreated] month HR 0.36, 95%CI, 0.14-0.94; p=0.002), but not in those with normal DPC4 expreion. PD-ECGF expreion and MVD were not aociated with survival. Conclusio: VEGF (stimulator) and DPC4 (inhibitor) are important regulators of pancreatic tumor angiogenesis and predictive of benefit from adjuvant therapy in resected pancreatic cancer. This suggests that adjuvant therapy may be both anti-angiogenic and cytotoxic. Addition of anti-VEGF agents to adjuvant regime may further improve outcomes.



上一篇:Meta分析证明:吉西他滨联合顺铂治疗晚期胰腺癌与吉西他滨单药比较无生存优势
下一篇:我国胰腺癌部分发病危险因素的Meta分析
使用“←” “→”快捷翻页
作者:游客
您需要登录后才可以回帖 登录 | 立即注册

请遵守医术天地社区公约言论规则,不得违反国家法律法规

猜你喜欢

  • 冷冻消融,在肾癌治疗中显优势

  • 基因检测有什么用途?基因检测有用吗?

  • 干细胞治疗——让盲人重建光明

  • 干细胞储存有必要吗?该如何存储?

    友情链接:
    复大官方网站
    -
    亚西亚健康网
    -
    重庆肛肠医院
    -
    名医博客
    -
    抗癌资讯

    sitemap|网站地图|手机版|

    医术天地 (琼B2-20040038-1)

       

    快速回复 返回顶部 返回列表